Literature DB >> 3515929

Metabolism and disposition of buspirone.

R E Gammans, R F Mayol, J A LaBudde.   

Abstract

The metabolism and disposition of buspirone have been studied in the rat, the monkey, and in more than 150 human subjects. Buspirone is well absorbed, but is subject to first-pass metabolism. The mean systemic availability is approximately 4 percent. Buspirone is eliminated primarily by oxidative metabolism, which produces several hydroxylated metabolites, including 5-hydroxy-buspirone and 1-pyrimidinylpiperazine. The latter metabolite is from 1 to 20 percent as potent as buspirone in a variety of pharmacologic tests; 5-hydroxybuspirone is essentially inactive. In humans, the systemic exposure to buspirone increases linearly in relation to the oral dose. Food increases the bioavailability of buspirone by decreasing first-pass metabolism; absorption is not markedly altered. The pharmacokinetics of buspirone were not significantly different in men and women or in individuals 21 to 40 years old compared with those over 65 years of age. Half-life values observed in healthy volunteers ranged from two to 33 hours. Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours. The half-life in women tended to be slightly longer than in men, but the difference was not significant. Hepatic cirrhosis resulted in a marked decrease in the clearance of buspirone, which correlated with serum alkaline phosphatase activity. Renal disease produced a modest decrease in buspirone clearance, which could not be correlated with an objective clinical measurement reflecting the severity of renal impairment. Buspirone was not removed by hemodialysis. Buspirone is highly protein bound (more than 95 percent), interacting with both albumin and alpha-acid glycoprotein. However, buspirone did not displace dilantin, propranolol, digoxin, or warfarin from plasma proteins. In rats, buspirone neither inhibited nor induced hepatic mixed-function oxidases. Co-administration of buspirone with amitriptyline or diazepam did not alter the disposition of these agents or their demethylated metabolites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515929     DOI: 10.1016/0002-9343(86)90331-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  35 in total

1.  Serotonin, gastric emptying, and dyspepsia.

Authors:  I Anderson
Journal:  BMJ       Date:  1992-11-21

Review 2.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Effect of buspirone: An anxiolytic drug on blood glucose in humans.

Authors:  S K Ojha; M Nandave; C Sharma
Journal:  Indian J Clin Biochem       Date:  2006-09

4.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

5.  Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.

Authors:  I Berlin; S Chalon; C Payan; G Schöllnhammer; F Cesselin; O Varoquaux; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

6.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.

Authors:  Yongkai Cao; Ningning Sun; Jiumei Zhang; Zhiguo Liu; Yi-Zhe Tang; Zhengzhi Wu; Kyeong-Man Kim; Seung Hoon Cheon
Journal:  Medchemcomm       Date:  2018-06-14       Impact factor: 3.597

7.  Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.

Authors:  S Caccia; G L Vigano; G Mingardi; S Garattini; R E Gammans; M Placchi; R F Mayol; M Pfeffer
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

8.  Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.

Authors:  P M Grasby; K J Friston; C Bench; P J Cowen; C D Frith; P F Liddle; R S Frackowiak; R J Dolan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

10.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.

Authors:  Kari Laine; Outi Ahokoski; Risto Huupponen; Jutta Hänninen; Sanna Palovaara; Jori Ruuskanen; Harry Björklund; Markku Anttila; Juha Rouru
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.